Eran Broshy, Director at Theravance Biopharma, Inc. (TBPH), sold 29,501 shares at $20.00 ($590K) on 2025-11-26, disclosed to the SEC on 2025-12-01.
Scheduled sale ($590k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.00 | 14,000 | $280K | 47.5% |
| 2 | $20.00 | 15,501 | $310K | 52.5% |
| Total | $20.00 avg | 29,501 | $590K | 100% |
| Filing → |
| MGLN | SELL | 2017-02-27 | $389K | — | Filing → |
| MGLN | SELL | 2016-12-12 | $182K | — | Filing → |
| VTIV | BUY | 2010-06-17 | $574K | — | Filing → |